Study shows heart risks may return after stopping GLP-1 drugs
Study shows heart risks may return after stopping GLP-1 drugs
Updated at: September 22, 2026 at 01:15 AM
Recent findings published in BMJ Medicine highlight a crucial concern for patients using GLP-1 receptor agonists, such as semaglutide and tirzepatide.
While these medications are known to significantly reduce the risk of major cardiovascular events like heart attacks and strokes, a large-scale study of over 333,000 veterans suggests that these benefits are not permanent.
The research indicates that heart protection begins to fade almost immediately after patients stop their treatment.
Notably, the risk of cardiovascular events increases progressively: by two years post-discontinuation, the protective benefits are largely erased.
Experts emphasize that GLP-1 therapy should be viewed as a long-term, chronic commitment rather than a temporary solution.
Although factors like high costs, side effects, and supply shortages often interrupt treatment, this study underscores the necessity of consistent adherence.
Even if patients restart therapy later, the initial 'scars' on heart health may be difficult to fully reverse.
Ultimately, these drugs provide vital heart benefits that extend beyond simple weight management, making long-term access and maintenance essential for high-risk patients.
